BNIP3-dependent mitophagy in the radio-resistant cancer cells relies on wild type p53 status to limit glycolytic remodeling, highlighting the potential use of drugs targeting glycolysis as an alternative strategy for overcoming radio-resistant cancers. This evidence concerns the gene BNIP3 and cancer.